| Name | Title | Contact Details |
|---|---|---|
Courtney Corcoran |
Chief Financial Officer | Profile |
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Find quality addiction treatment in North Carolina, where you’ll experience the care, flexibility, and support you need to conquer substance use.
BSI was founded by Judith C. McDowall in 1985 to prepare documentation for FDA regulatory submissions. BSI began preparing peer reviewed technical reports for the National Toxicology Program in 1989. We obtained and have retained this prestigious
United Medical Instruments is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kansas City Internal Medicine is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.